Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: fu p. Future Oncol. 2024 Dec 4:1-9. doi: 10.1080/14796694.2024.2430106. Online ahead of print. Future Oncol. 2024. PMID: 39628303 Free article.
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A, Zhang J, Liu X, Wu W, Liu Y, Fan Z, Zhang A, Zhou T, Fu P, Wang S, Ouyang Q, Tang J, Jiang H, Zhang X, Pang D, He J, Shi L, Wang X, Sheng Y, Mao D, Shao Z. Cao A, et al. Among authors: fu p. Health Qual Life Outcomes. 2016 Mar 24;14:51. doi: 10.1186/s12955-016-0446-2. Health Qual Life Outcomes. 2016. PMID: 27009092 Free PMC article. Clinical Trial.
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Yang F, Huang X, Sun C, Li J, Wang B, Yan M, Jin F, Wang H, Zhang J, Fu P, Zeng T, Wang J, Li W, Li Y, Yang M, Li J, Wu H, Fu Z, Yin Y, Jiang Z. Yang F, et al. Among authors: fu z, fu p. BMC Cancer. 2020 Mar 29;20(1):255. doi: 10.1186/s12885-020-6639-4. BMC Cancer. 2020. PMID: 32223744 Free PMC article.
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Qu X, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Wang J, Zhang H, Wang S, Zhang J, Jin F, Rao N, Ma B, He P, Xu B, Zhuang Z, Wang J, Sun Q, Guo X, Mo M, Shao Z; CBCSG010 Study Group. Li J, et al. Among authors: fu p. J Clin Oncol. 2020 Jun 1;38(16):1774-1784. doi: 10.1200/JCO.19.02474. Epub 2020 Apr 10. J Clin Oncol. 2020. PMID: 32275467 Free PMC article. Clinical Trial.
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020.
Li J, Wang H, Geng C, Liu Z, Lin Y, Nie J, Sun G, Ouyang Q, Wang X, Li X, Liu Y, Chen Q, Fu P, Yao F, Chen J, Chen Y, Zhao H, Yin Y, Zhang J, Chen J, Kong X, Cheng J, Zhang H, Peng S, Wang G, Jin F, Liu Y, Wu G, Sun S, Jiang Z. Li J, et al. Among authors: fu p. EClinicalMedicine. 2020 Sep 24;26:100503. doi: 10.1016/j.eclinm.2020.100503. eCollection 2020 Sep. EClinicalMedicine. 2020. PMID: 32989430 Free PMC article.
Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial.
Gao HF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, Zhang G, Fu P, Liu Z, Zhang LL, Yang CQ, Yang M, Zhu T, Ji F, Li JQ, Cheng MY, Wang K. Gao HF, et al. Among authors: fu p. Ther Adv Med Oncol. 2021 Apr 20;13:17588359211009003. doi: 10.1177/17588359211009003. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33959195 Free PMC article.
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer.
Zhu J, Jiao D, Yan M, Chen X, Wang C, Lu Z, Li L, Sun X, Qin L, Guo X, Zhang C, Qiao J, Li J, Fan Z, Wang H, Zhang J, Yin Y, Fu P, Geng C, Jin F, Jiang Z, Cui S, Liu Z. Zhu J, et al. Among authors: fu p. Front Oncol. 2021 Apr 29;11:675070. doi: 10.3389/fonc.2021.675070. eCollection 2021. Front Oncol. 2021. PMID: 33996607 Free PMC article.
Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in China.
Chow LW, Fu PF, Guo L, Hu XC, Jiang J, Lie EF, Liu J, Lu XH, Lu YK, Ma HM, Mo QG, Shi YX, Wang K, Wang MH, Wang S, Wang SS, Wang XM, Wang XJ, Wu HJ, Yang HJ, Yao HR, Zhang Y, Zhu L, On Behalf Of The Asian Institute Of Clinical Oncology Aico Expert Panel -. Chow LW, et al. Asian Pac J Cancer Prev. 2022 Feb 1;23(2):379-382. doi: 10.31557/APJCP.2022.23.2.379. Asian Pac J Cancer Prev. 2022. PMID: 35225446 Free PMC article.
3,090 results